<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1) *
ENDOSONICS CORPORATION
--------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE PER SHARE
--------------------------------------------------
(Title of Class of Securities)
29264K105
------------------------------------------------
(CUSIP Number)
GILBERT H. DAVIS, ESQ.
SIMS MOSS KLINE & DAVIS LLP
400 NORTHPARK TOWN CENTER, SUITE 310
1000 ABERNATHY ROAD, N.E.
ATLANTA, GEORGIA 30328
(770) 481-7200
------------------------------------------------
(Name, Address and Telephone Number of Persons
Authorized to Receive Notices and Communications)
JULY 22, 1998
-------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are sent.
Page 1 of 5 Pages
<PAGE>
13D
CUSIP No. 29264k105
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
James O. Patterson
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS: WC, OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION: United States
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER: 662,500
SHARES ---------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER: NONE
OWNED BY ----------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER: 662,500
REPORTING ----------------------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER: NONE
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 662,500
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 4.09258
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON: IN
- --------------------------------------------------------------------------------
Page 2 of 5 Pages
<PAGE>
Pursuant to Rule 13d-2(a) of Regulation 13D-G of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended (the "Act"),
the undersigned hereby amend their Schedule 13D Statement dated June 19, 1998
relating to the common stock, $.001 par value, of Endosonics Corporation
("Company") (such initial Schedule 13D shall hereinafter be referred to as the
"Statement"). Unless otherwise indicated, all defined terms used in this
Amendment No. 1 to the Statement (this "Amendment") shall have the same meanings
as those set forth in the Statement. There has been no material change in the
information included in the Statement except as regards the information
contained in Item 5 of the Statement, which is supplemented as set forth below.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
------------------------------------
As of July 22, 1998, Phoenix, Falcon Fund and Mustang had sold shares of
Company stock such that Mr. Patterson's beneficial ownership had been reduced to
662,500 shares, or approximately 4.09258% of outstanding shares. Of those
shares, 262,286 (1.62026% of outstanding shares) were owned directly by Phoenix;
200,214 (1.23681% of outstanding shares) were owned directly by Falcon Fund and
200,000 (1.23549% of outstanding shares) were owned directly by Mustang. As a
result of such sales and as of the date of this Amendment, Mr. Patterson,
Phoenix, Falcon Fund and Mustang owned less than 5.0% of the outstanding shares
of Company stock. As a result, no further amendments to the Statement will be
made unless and until beneficial ownership of Company common stock again exceeds
5.0% of outstanding shares.
The percentages of outstanding shares of the Company stock set out in the
preceding paragraph are computed based on a total of 16,187,830 outstanding
shares of Company stock as of May 15, 1998, as indicated by the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.
Page 3 of 5 Pages
<PAGE>
During the 60 days prior to July 22, 1998, the parties filing the Statement
have engaged in the following transactions in shares of the Company stock:
<TABLE>
<CAPTION>
NO. OF SHARES PRICE
DATE PARTY PURCHASED/(SOLD) PER SHARE
--------- ------------- ---------------- ---------
<S> <C> <C> <C>
07/22/98 Phoenix (14,659) $8.8125
07/22/98 Phoenix (29,318) $8.5625
07/22/98 Phoenix (58,636) $8.4844
07/20/98 Phoenix (63,033) $8.9026
07/17/98 Phoenix (41,050) $8.5357
06/24/98 Phoenix 8,858 $5.8125
06/19/98 Phoenix 88,535 $6.0000
06/18/98 Phoenix 29,512 $5.9843
07/22/98 Falcon Fund (41,364) $8.4844
07/22/98 Falcon Fund (20,682) $8.5625
07/22/98 Falcon Fund (10,341) $8.8125
07/20/98 Falcon Fund (44,467) $8.9026
07/17/98 Falcon Fund (28,950) $8.5357
06/24/98 Falcon Fund 6,142 $5.8125
06/19/98 Falcon Fund 61,465 $6.0000
06/18/98 Falcon Fund 20,488 $5.9843
06/19/98 Mustang 200,000 $ 6.000
</TABLE>
Each of the above transactions was effected on the open market through the
National Association of Securities Dealers, Inc. Automated Quotation Systems
(NASDAQ).
Page 4 of 5 Pages
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
/s/ James O. Patterson
Date: July 22, 1998 ------------------------------------
James O. Patterson
PHOENIX
Date: July 22, 1998 By: /s/ James O. Patterson
---------------------------------
James O. Patterson, Managing
General Partner
FALCON FUND INTERNATIONAL
PARTNERSHIP
By: Falcon Fund, Investment
General Partner
By: J.O. Patterson & Co., General
Partner
Date: July 22, 1998 By: /s/ James O. Patterson
---------------------------------
James O. Patterson, President
Page 5 of 5 Pages
